IP Library › Granted Patent US 9,234,021
Granted Patent B2
US 9,234,021 · App. 14/257,772 · Granted Jan 12, 2016

Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha V beta 3 integrin

Inventors: Jennifer R. Cochran (Stanford, CA); Adam Silverman (Redwood City, CA); Douglas Jones (Newton, MA); Niv Papo (Palo Alto, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C07K14/515A61K38/18A61K38/1858A61K47/48007C07K14/475A61K38/1866A61K2123/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,234,021
App. No.
14/257,772
Granted
Jan 12, 2016
Kind
B2
Abstract

Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.

Claims (2)

1. A polypeptide comprising an integrin-recognition RGD motif having a sequence selected from the group consisting of: SEQ ID NOs: 29-35, 37-40, 42-53, 55, and 55-64.

2. A composition comprising a polypeptide according to claim 1 and a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2014
From: COCHRAN, JENNIFER R.; SILVERMAN, ADAM; JONES, DOUGLAS; PAPO, NIV
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 033387/0744 →
Continuity (3)
Continuation 13145059
Provisional Application 61145579 · Jan 18, 2009
Related Publication 20140356286A1 · Dec 4, 2014